FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977166543> ?p ?o ?g. }

• W2977166543 endingPage "2429" @default.
• W2977166543 startingPage "2418" @default.
• W2977166543 abstract "Abstract Study Question Is hormone replacement therapy (HRT) associated with an increased risk of melanoma skin cancer or prognostic outcomes amongst post-menopausal women? SUMMARY ANSWER Whilst we found evidence of an association with melanoma risk, the lack of dose-response and associations observed with recent use, localised disease and intravaginal oestrogens suggests this is a non-causal association. WHAT IS KNOWN ALREADY Evidence on HRT and melanoma risk remains inconclusive, with studies providing conflicting results. Furthermore, evidence on melanoma survival is sparse, with only one previous study reporting protective associations with HRT use, likely attributable to immortal time bias. STUDY DESIGN, SIZE, DURATION We conducted a nation-wide population-based case-control study and a retrospective cohort study utilising the Danish healthcare registries. Case-control analyses included 8279 women aged 45–85 with a first-ever diagnosis of malignant melanoma between 2000 and 2015, matched by age and calendar time to 165 580 population controls. A cohort of 6575 patients with a diagnosis of primary malignant melanoma between 2000 and 2013 and followed through 2015 was examined to determine if HRT use had an impact on melanoma survival outcomes. PARTICIPANTS/MATERIALS, SETTING, METHODS Based on prescriptions dispensed since 1995, ever-use of HRT was defined as having filled at least one prescription for HRT prior to the index date. In total, 2629 cases (31.8%) and 47 026 controls (28.4%) used HRT. Conditional logistic regression was used to calculate odds ratios (ORs) for melanoma risk according to HRT use, compared with non-use, adjusting for potential confounders. For cohort analyses, Cox proportional hazards models was used to estimate adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for second melanoma incidence and all-cause mortality associated with HRT. MAIN RESULTS AND THE ROLE OF CHANCE High use of HRT was associated with an OR of 1.21 (95% CI 1.13–1.29) for melanoma risk, with no evidence of a dose-response pattern. Results were most pronounced amongst recent high users (OR, 1.28; 95% CI 1.17–1.41), for localised disease (OR, 1.25; 95% CI 1.15–1.36) and for intravaginal oestrogen therapy (OR, 1.38; 95% CI 1.13–1.68). Compared with non-use, there was no evidence of an association for secondary melanoma for post-diagnostic new-use (fully adjusted HR, 1.56; 95% CI 0.64–3.80) or continuous HRT use (fully adjusted HR, 1.26; 95% CI 0.89–1.78). Similar associations were observed for all-cause mortality. LIMITATIONS, REASONS FOR CAUTION Despite the large sample size and the use of robust population-based registries with almost complete coverage, we lacked information on some important confounders including sun exposure. WIDER IMPLICATIONS OF THE FINDINGS Whilst we cannot rule out an association between HRT use and melanoma risk, the associations observed are also compatible with increased healthcare utilisation and thus increased melanoma detection amongst HRT users. No association between HRT use and melanoma survival outcomes was observed. This should provide some reassurance to patients and clinicians, particularly concerning the use of HRT in patients with a history of melanoma. STUDY FUNDING/COMPETING INTEREST(S) B.M.H. is funded by a Cancer Research UK Population Research Postdoctoral Fellowship. The funding source had no influence on the design or conduct of this study. A.P. reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Servier, Novo Nordisk and LEO Pharma, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this article. The other authors have no competing interests to declare. TRIAL REGISTRATION NUMBER N/A." @default.
• W2977166543 created "2019-10-03" @default.
• W2977166543 creator A5018562618 @default.
• W2977166543 creator A5020963806 @default.
• W2977166543 creator A5071893340 @default.
• W2977166543 creator A5072859924 @default.
• W2977166543 creator A5089401828 @default.
• W2977166543 date "2019-12-01" @default.
• W2977166543 modified "2023-10-17" @default.
• W2977166543 title "Hormone replacement therapy and the risk of melanoma in post-menopausal women" @default.
• W2977166543 cites W1872396144 @default.
• W2977166543 cites W1969186806 @default.
• W2977166543 cites W1971352053 @default.
• W2977166543 cites W1978670003 @default.
• W2977166543 cites W1982394778 @default.
• W2977166543 cites W1997144004 @default.
• W2977166543 cites W2000445173 @default.
• W2977166543 cites W2013273470 @default.
• W2977166543 cites W2028071743 @default.
• W2977166543 cites W2028864050 @default.
• W2977166543 cites W2029462200 @default.
• W2977166543 cites W2033939891 @default.
• W2977166543 cites W2039530273 @default.
• W2977166543 cites W2040714593 @default.
• W2977166543 cites W2052253052 @default.
• W2977166543 cites W2067772399 @default.
• W2977166543 cites W2068568330 @default.
• W2977166543 cites W2082638273 @default.
• W2977166543 cites W2083955434 @default.
• W2977166543 cites W2086392048 @default.
• W2977166543 cites W2097206214 @default.
• W2977166543 cites W2097769613 @default.
• W2977166543 cites W2100208125 @default.
• W2977166543 cites W2115294219 @default.
• W2977166543 cites W2121962845 @default.
• W2977166543 cites W2122985624 @default.
• W2977166543 cites W2124943672 @default.
• W2977166543 cites W2130207881 @default.
• W2977166543 cites W2131467528 @default.
• W2977166543 cites W2140483955 @default.
• W2977166543 cites W2142749836 @default.
• W2977166543 cites W2151278054 @default.
• W2977166543 cites W2154683287 @default.
• W2977166543 cites W2157375341 @default.
• W2977166543 cites W2160208506 @default.
• W2977166543 cites W2161893805 @default.
• W2977166543 cites W2162544134 @default.
• W2977166543 cites W2219591537 @default.
• W2977166543 cites W2462936639 @default.
• W2977166543 cites W2530290395 @default.
• W2977166543 cites W2532983714 @default.
• W2977166543 cites W2541013163 @default.
• W2977166543 cites W2729812310 @default.
• W2977166543 cites W2731800117 @default.
• W2977166543 cites W2734991617 @default.
• W2977166543 cites W2750677670 @default.
• W2977166543 cites W2775502046 @default.
• W2977166543 cites W2912705052 @default.
• W2977166543 cites W2917198157 @default.
• W2977166543 cites W2954306655 @default.
• W2977166543 cites W354536254 @default.
• W2977166543 cites W4321429430 @default.
• W2977166543 doi "https://doi.org/10.1093/humrep/dez222" @default.
• W2977166543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31803923" @default.
• W2977166543 hasPublicationYear "2019" @default.
• W2977166543 type Work @default.
• W2977166543 sameAs 2977166543 @default.
• W2977166543 citedByCount "13" @default.
• W2977166543 countsByYear W29771665432020 @default.
• W2977166543 countsByYear W29771665432021 @default.
• W2977166543 countsByYear W29771665432022 @default.
• W2977166543 countsByYear W29771665432023 @default.
• W2977166543 crossrefType "journal-article" @default.
• W2977166543 hasAuthorship W2977166543A5018562618 @default.
• W2977166543 hasAuthorship W2977166543A5020963806 @default.
• W2977166543 hasAuthorship W2977166543A5071893340 @default.
• W2977166543 hasAuthorship W2977166543A5072859924 @default.
• W2977166543 hasAuthorship W2977166543A5089401828 @default.
• W2977166543 hasBestOaLocation W29771665432 @default.
• W2977166543 hasConcept C126322002 @default.
• W2977166543 hasConcept C143998085 @default.
• W2977166543 hasConcept C156957248 @default.
• W2977166543 hasConcept C167135981 @default.
• W2977166543 hasConcept C201903717 @default.
• W2977166543 hasConcept C2426938 @default.
• W2977166543 hasConcept C2777658100 @default.
• W2977166543 hasConcept C2779279991 @default.
• W2977166543 hasConcept C2780159708 @default.
• W2977166543 hasConcept C2908647359 @default.
• W2977166543 hasConcept C29456083 @default.
• W2977166543 hasConcept C502942594 @default.
• W2977166543 hasConcept C71924100 @default.
• W2977166543 hasConcept C72563966 @default.
• W2977166543 hasConcept C98274493 @default.
• W2977166543 hasConcept C99454951 @default.
• W2977166543 hasConceptScore W2977166543C126322002 @default.
• W2977166543 hasConceptScore W2977166543C143998085 @default.
• W2977166543 hasConceptScore W2977166543C156957248 @default.

• next